Research

Part of INSERM Unit 1232 interesting in epigenetics and cancer located at Institut de Cancérologie de l'Ouest as closely as possible to the patients.

​

Our lab is interested in understanding how epigenetic and epitranscriptomic malign mechanisms contribute to cancer initiation/progression, and promote resistance to anticancer therapies.

​

In this context, we aim at

1) developing novel highly selective epidrugs and

2) preventing the pesticides-induced epigenetic reprogramming that promote the tumorigenesis.

​

We are also interested in detection of circulating epimarks acting as "warning" for a cancer predisposition", "red fire" for stopping anticancer therapies, or acting as "green fire" for guiding the administration of anticancer therapies.